Experience on board
10.02.2016 - Barcelona-based orphan disease specialist Minoryx Therapeutics has appointed Khalid Islam as the new chairman of its board of directors. Until 2014, Islam served as chairman and CEO of Gentium S.p.A., an Italian manufacturer of active pharmaceutical ingredients.
Before taking over at Gentium, Islam was president and CEO Arpida AG, where he was instrumental in listing the of Swiss biopharma company on SWX. Before that, he worked in academia at University of London’s Imperial College and at Milan University. He has published more than 85 scientific articles and sits on the editorial board of Current Drug Discovery and Technologies. Islam is currently the chairman of US company Fennec and a member of the board of directors at Swedish Karolinska Development, Italian Molmed and Swedish OxThera.http://www.european-biotechnology-news.com/people/bio-people/2016/khalid-islam.html